Revision of Consolidated Business Results Forecasts for the Fiscal Year Ending March 31, 2026
Takara Holdings (the “Company”) announces revisions to the business results forecasts for the fiscal year ending March 31, 2026 (from April 1, 2025, to March 31, 2026) that it released on May 13, 2025, as stated below. These revisions were based on consideration of recent performance trends.
1. Revised figures for the fiscal year ending March 31, 2026 (from April 1, 2025, to March 31, 2026)
| (Millions of yen / %) |
|
|
2. Reason for revision
For the fiscal year ending March 31, 2026, The Takara Shuzo International Group is projected to exceed prior expectations, driven by strong performance in the overseas alcoholic beverage business and additional contributions from M&A activities in Japanese food wholesale business in overseas markets. In contrast, Takara Shuzo is expected to fall short of the previous forecast due to a decline in shochu and other products. The Takara Bio Group, however, is anticipated to fall short of forecast, reflecting continued stagnation in the global life science research market and failure to secure new contracts in the CDMO business in Japan. Consequently, consolidated net sales for the Group are expected to fall below the previous forecast.
Operating income is expected to exceed the previous forecast for Takara Shuzo, despite lower gross profit, due to efficient management of selling, general and administrative expenses. For the Takara Shuzo International Group, although the Japanese food wholesale business in overseas markets is expected to fall short due to intensified competition and increased SG&A expenses, the overseas alcoholic beverage business is performing well and is expected to exceed the previous forecast. The Takara Bio Group is projected to post an operating loss due to the significant impact of declining sales. As a result, consolidated operating income for the Group is also expected to fall below the previous forecast.
Net income attributable to owners of the parent is expected to fall below the previous forecast. Although extraordinary gains are anticipated to increase due to the sale of investment securities and fixed assets, extraordinary losses are also expected to increase, mainly due to impairment losses related to the Takara Bio Group. In addition, the partial reversal of deferred tax assets is expected to have negative impact on the company.
For details of the revised segment forecasts, please refer to the “Supplement for the Consolidated Financial Statements for the Second Quarter Ended September 30, 2025” (Pages 10/15 to 13/15), disclosed today.
Additionally, our consolidated subsidiary, Takara Bio Inc. (Code: 4974, TSE Prime Market), has also revised its consolidated earnings forecast for the fiscal year ending March 31, 2026.
* The above-mentioned forecasts have been prepared based on the information available as of the date of announcement of this
document and could differ from the actual results, etc.
